Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1964335

Santaris Pharma A/S - Product Pipeline Review - H2 2011

Description:
Santaris Pharma A/S – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Santaris Pharma A/S - Product Pipeline Review - H2 2011” provides data on the Santaris Pharma A/S’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Santaris Pharma A/S’s corporate website, SEC filings, investor presentations and featured press releases, both from Santaris Pharma A/S and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Santaris Pharma A/S - Brief Santaris Pharma A/S overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Santaris Pharma A/S human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Santaris Pharma A/S with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Santaris Pharma A/S’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Santaris Pharma A/S’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Santaris Pharma A/S in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Santaris Pharma A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Santaris Pharma A/S.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Santaris Pharma A/S and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Santaris Pharma A/S; Santaris Pharma A/S - Key Therapeutics; Santaris Pharma A/S - Pipeline Overview and Promising Molecules; Santaris Pharma A/S - News; Santaris Pharma A/S - Latest Updates; Santaris Pharma A/S - Pipeline; Santaris Pharma A/S - Discontinued/Dormant Projects
 
Contents:


List of Tables
List of Figures
Santaris Pharma A/S Snapshot
Santaris Pharma A/S Overview
Key Information
Key Facts
Santaris Pharma A/S – Research and Development Overview
Key Therapeutic Areas
Santaris Pharma A/S – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Santaris Pharma A/S – Pipeline Products Glance
Santaris Pharma A/S Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Santaris Pharma A/S – Drug Profiles
SPC2996
Product Description
Mechanism of Action
R&D Progress
SPC4955
Product Description
Mechanism of Action
R&D Progress
Santaris Pharma A/S – Pipeline Analysis
Santaris Pharma A/S – Pipeline Products by Therapeutic Class
Santaris Pharma A/S - Pipeline Products By Target
Santaris Pharma A/S – Pipeline Products by Route of Administration
Santaris Pharma A/S – Pipeline Products by Molecule Type
Santaris Pharma A/S – Recent Pipeline Updates
Santaris Pharma A/S – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 30, 2007: Enzon Initiates Second Phase I Study Of Its HIF-1 Alpha Antagonist
Oct 28, 2008: Enzon's HIF-1 Alpha Antagonist Shows Antitumor Activity
May 28, 2008: Santaris Pharma Begins Human Clinical Testing Of The World’s First MicroRNA SPC3649
Jul 27, 2006: Enzon Pharmaceuticals And Santaris Pharma Enter Into Global Collaboration To Develop Novel Cancer Therapeutics
Apr 26, 2010: Santaris Advances SPC5001 Into Drug Development For Treatment Of High Cholesterol
Jan 25, 2007: Enzon Receives FDA Clearance of HIF-1 alpha Investigational New Drug Application
Sep 22, 2010: Santaris Pharma Initiates Phase II Clinical Trial With Miravirsen For Treatment Of Hepatitis C Virus
Apr 22, 2010: EZN 3920 Enzon Preclinical Data
Mar 20, 2009: Another LNA-based RNA Inhibitor Enters Clinical Trials
Mar 20, 2009: Santaris Pharma Announces That The Fourth LNA-Based Drug Has Been Brought Into The Clinic
Dec 19, 2007: GlaxoSmithKline And Santaris Pharma Enter Global R&D Alliance To Discover Develop And Commercialize RNA Antagonists As Novel Antivirals
Dec 19, 2007: GlaxoSmithKline And Santaris Pharma Enter Global R&D Alliance To Discover, Develop And Commercialise RNA Antagonists As Novel Antivirals
Apr 18, 2007: Bcl-2 Antagonist shown To Be Therapeutically Effective In A Mouse Model Of Chronic Lymphocytic Leukaemia
Apr 18, 2007: Santaris Pharma Presents Positive Preclinical Data On SPC2996 At The American Association For Cancer Research
Jul 17, 2006: Enzon Pharmaceuticals And Santaris Pharma Enter Into Global Collaboration To Develop Novel Cancer Therapeutics
Jun 11, 2007: Santaris Pharma Shows Strong Phase I/II Data In CLLSPC2996
May 11, 2011: Santaris Pharma Advances Second Drug From Cardiometabolic program, SPC4955 Into Phase I Clinical Trials For Treatment Of High Cholesterol
Feb 10, 2009: Enzon Announces IND Acceptance For Its Survivin Antagonist
Nov 08, 2005: Santaris Pharma Announces IND Approval Of SPC2996 For The Treatment Of Cancer
Sep 07, 2011: Santaris Pharma Showcases MicroRNA And mRNA Research Advancements Utilizing Its LNA Technology At OTS Meeting
Jun 04, 2009: LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs Of Clinical Benefit
May 04, 2011: Santaris Pharma Advances SPC5001 Into Phase I Clinical Trials For Treatment Of High Cholesterol
Jan 04, 2007: Enzon Pharmaceuticals Files Investigational New Drug Application For Novel HIF-1alpha Antagonist In Cancer
Dec 03, 2009: Santaris Announces The Development Of SPC3649 For The Treatment Of Hepatitis C Virus (HCV) Infections In Chimpanzees
Nov 02, 2007: Santaris Pharma’s HIF-1 Alpha Antagonist Begins Second Phase I Study
Jun 01, 2009: Enzon Presents Clinical Data From HIF-1 Alpha Antagonist Study At ASCO
Financial Deals Landscape
Santaris Pharma A/S, Deals Summary
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Santaris Pharma Secures $30 Million In Series C Financing
Santaris Pharma Secures $48.3 Million In Venture Financing
Santaris Pharma Secures $5.36 Million In First Closing Of Series B Financing
Partnerships
Santaris Pharma Expands Its Collaboration With Pfizer
Santaris Pharma Enters Into Strategic Alliance With miRagen Therapeutics
Shire Enters Into Research Agreement With Santaris Pharma
Wyeth Pharmaceuticals Enters Into An Agreement With Santaris Pharma
GlaxoSmithKline Enters Into An Agreement With Santaris Pharma
Enzon Pharmaceuticals Signs Agreement With Santaris Pharma
Santaris Pharma Enters Into Research Agreement With University of Copenhagen
Licensing Agreements
Santaris Pharma Enters Into Licensing Agreement With Massachusetts General Hospital
Equity Offering
Santaris Pharma Completes Private Placement Of $5 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Santaris Pharma A/S – Pipeline by Therapy Area and Indication, H2 2011
Santaris Pharma A/S – Pipeline by Stage of Development, H2 2011
Santaris Pharma A/S – Monotherapy Products in Pipeline, H2 2011
Santaris Pharma A/S - Phase II, H2 2011
Santaris Pharma A/S - Phase I, H2 2011
Santaris Pharma A/S - Pipeline By Therapeutic Class, H2 2011
Santaris Pharma A/S - Pipeline By Target, H2 2011
Santaris Pharma A/S – Pipeline By Route of Administration, H2 2011
Santaris Pharma A/S – Pipeline By Molecule Type, H2 2011
Santaris Pharma A/S – Recent Pipeline Updates, H2 2011
Santaris Pharma A/S, Other Locations
Santaris Pharma A/S, Deals Summary
Santaris Pharma Secures $30 Million In Series C Financing
Santaris Pharma Secures $48.3 Million In Venture Financing
Santaris Pharma Secures $5.36 Million In First Closing Of Series B Financing
Santaris Pharma Expands Its Collaboration With Pfizer
Santaris Pharma Enters Into Strategic Alliance With miRagen Therapeutics
Shire Enters Into Research Agreement With Santaris Pharma
Wyeth Pharmaceuticals Enters Into An Agreement With Santaris Pharma
GlaxoSmithKline Enters Into An Agreement With Santaris Pharma
Enzon Pharmaceuticals Signs Agreement With Santaris Pharma
Santaris Pharma Enters Into Research Agreement With University of Copenhagen
Santaris Pharma Enters Into Licensing Agreement With Massachusetts General Hospital
Santaris Pharma Completes Private Placement Of $5 Million

List of Figures
Santaris Pharma A/S – Pipeline by Therapy Area and Indication, H2 2011
Santaris Pharma A/S – Pipeline by Stage of Development, H2 2011
Santaris Pharma A/S – Monotherapy Products in Pipeline, H2 2011
Santaris Pharma A/S – Pipeline By Therapeutic Class, H2 2011
Santaris Pharma A/S – Pipeline By Route of Administration, H2 2011
Santaris Pharma A/S – Pipeline By Molecule Type, H2 2011
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1964335

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Oct 31th 2014
12:16:46 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Santaris Pharma A/S - Product Pipeline Review - H2 2011

Web Address

http://www.researchandmarkets.com/reports/1964335

Office Code

SCOI7T

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 500
Electronic (PDF) - Site License USD 1,000
Electronic (PDF) - Enterprisewide USD 1,500

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Oct 31th 2014
12:16:46 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)